Lidia Sambucetti, Ph.D., directs cancer drug discovery efforts and collaborates with scientific and business development colleagues to advance SRI’s oncology pipeline.
Sambucetti leads a team of scientists focused on the development of new technology platforms for identifying and analyzing circulating tumor cells from blood samples (i.e., liquid biopsies), including the novel fiber‐optic array scanning technology (FAST) circulating tumor cell detection system, which can uniquely distinguish a single tumor cell among tens of millions of healthy cells in just a few minutes.
Prior to joining SRI, Sambucetti served as the director of biochemistry at Telik, Inc., a biopharmaceutical company developing small molecule drugs to treat cancer and other serious diseases. Sambucetti has also served as the director of drug screening and toxicology at Xenogen Corporation and as a team leader in the oncology program at Novartis Pharmaceutical Corporation.
Sambucetti has published more than 20 papers in peer-reviewed publications such as Science, Cell and Cancer Research. She is a member of the American Association for Cancer Research and has received various industry honors and awards. Sambucetti received her Ph.D. in molecular biology from Albert Einstein College of Medicine and completed postdoctoral work at Stanford University and the Roche Institute of Molecular Biology.